{"id":11676,"date":"2020-07-02T08:28:06","date_gmt":"2020-07-02T16:28:06","guid":{"rendered":"https:\/\/drugpolicy.ca\/?p=11676"},"modified":"2021-11-07T14:25:34","modified_gmt":"2021-11-07T22:25:34","slug":"expanded-response-options-to-opioid-harms-case-study-from-four-canadian-cities","status":"publish","type":"post","link":"https:\/\/www.drugpolicy.ca\/fr\/expanded-response-options-to-opioid-harms-case-study-from-four-canadian-cities\/","title":{"rendered":"Expanded Response Options to Opioid Harms: Case Study from Four Cities"},"content":{"rendered":"\n<p style=\"color:#f5f5f5; margin-bottom:-30px\">CCSA case study, CCSA case study<\/p>\n\n\n\n<iframe loading=\"lazy\" class=\"scribd_iframe_embed\" title=\"CCSA Expanded Response Options Opioid Harms Case Studies 2020 En\" src=\"https:\/\/www.scribd.com\/embeds\/467756651\/content?start_page=1&amp;view_mode=scroll&amp;access_key=key-GbycMnVc37rkqkpJhBx9\" data-auto-height=\"false\" data-aspect-ratio=\"0.7729220222793488\" scrolling=\"no\" id=\"doc_59420\" width=\"100%\" height=\"600\" frameborder=\"0\"><\/iframe>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link has-background\" href=\"https:\/\/drugpolicy.ca\/wp-content\/uploads\/2020\/07\/CCSA-Expanded-Response-Options-Opioid-Harms-Case-Studies-2020-en.pdf\" style=\"background-color:#c42127\" target=\"_blank\" rel=\"noreferrer noopener\">Download PDF<\/a><\/div>\n<\/div>\n\n\n\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p style=\"text-align:center\"><strong>Click <a href=\"https:\/\/drugpolicy.ca\/covid-19-harm-reduction-resources\/\" target=\"_blank\" aria-label=\"undefined (opens in a new tab)\" rel=\"noreferrer noopener\">HERE<\/a> for more resources<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&#8220;Canada is facing an urgent challenge to reduce the harms associated<br>with the problematic use of opioids. More than 14,700 lives were lost to deaths apparently related to opioids between January 2016 and September 2019. During that same period, there were 19,490 hospitalizations for poisoning related opioid to opioids (Special Advisory Committee on the Epidemic of Opioid Overdoses, 2019). The COVID-19 pandemic compounds this ongoing public health crisis. There is a heightened need to reduce avoidable pressures on healthcare systems and support people who use opioids who may be at increased risk or unable to self-isolate during the pandemic.&#8221;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Source: <a href=\"https:\/\/www.ccsa.ca\/\">Canadian Centre on<\/a><a href=\"https:\/\/www.ccsa.ca\/\" target=\"_blank\" aria-label=\"undefined (opens in a new tab)\" rel=\"noreferrer noopener\"> Substance Use<\/a><\/em><\/p>\n\n\n\n<div class=\"widget signup-widget mb-5\">\r\n<p class=\"lead\"><strong>\u00cates-vous pr\u00eat(e) \u00e0 aider ?<\/strong><\/p>\r\n<p>Soutenez des politiques sur les drogues bas\u00e9es sur la justice sociale, la compassion et les preuves. Inscrivez-vous \u00e0 notre newsletter pour obtenir des mises \u00e0 jour et d\u00e9couvrez comment vous pouvez agir avec nous.<\/p>\r\n<!-- form.123formbuilder.com script begins here --><script type=\"text\/javascript\" defer=\"defer\" src=\"https:\/\/form.123formbuilder.com\/embed\/6415583.js\" data-role=\"form\" data-default-width=\"650px\"><\/script><!-- form.123formbuilder.com script ends here -->\r\n<\/div>\r\n","protected":false},"excerpt":{"rendered":"<p>COVID-19 pandemic compounds an ongoing public health crisis. There is a heightened need to reduce avoidable pressures on healthcare systems and support people who use opioids.<\/p>\n","protected":false},"author":38,"featured_media":11674,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_crdt_document":"","footnotes":""},"categories":[1120],"tags":[1126,1124,1127],"class_list":["post-11676","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-covid-research","tag-miscellaneous","tag-safe-supply-oat-and-ioat","tag-safer-drug-use"],"acf":[],"mb":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Expanded Response Options to Opioid Harms: Case Study from Four Cities - Canadian Drug Policy Coalition<\/title>\n<meta name=\"description\" content=\"COVID-19 pandemic compounds ongoing public health crisis. There&#039;s greater need to reduce pressures on healthcare system and support PWUD | CCSA case study\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.drugpolicy.ca\/fr\/expanded-response-options-to-opioid-harms-case-study-from-four-canadian-cities\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Expanded Response Options to Opioid Harms: Case Study from Four Cities - Canadian Drug Policy Coalition\" \/>\n<meta property=\"og:description\" content=\"COVID-19 pandemic compounds ongoing public health crisis. There&#039;s greater need to reduce pressures on healthcare system and support PWUD | CCSA case study\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.drugpolicy.ca\/fr\/expanded-response-options-to-opioid-harms-case-study-from-four-canadian-cities\/\" \/>\n<meta property=\"og:site_name\" content=\"Canadian Drug Policy Coalition\" \/>\n<meta property=\"article:published_time\" content=\"2020-07-02T16:28:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-11-07T22:25:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2020\/07\/Screen-Shot-2020-07-02-at-9.00.04-AM.png\" \/>\n\t<meta property=\"og:image:width\" content=\"922\" \/>\n\t<meta property=\"og:image:height\" content=\"669\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Canadian Drug Policy Coalition\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Canadian Drug Policy Coalition\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/expanded-response-options-to-opioid-harms-case-study-from-four-canadian-cities\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/expanded-response-options-to-opioid-harms-case-study-from-four-canadian-cities\\\/\"},\"author\":{\"name\":\"Canadian Drug Policy Coalition\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#\\\/schema\\\/person\\\/c32110f234bdb1f5d978710b6b406a30\"},\"headline\":\"Expanded Response Options to Opioid Harms: Case Study from Four Cities\",\"datePublished\":\"2020-07-02T16:28:06+00:00\",\"dateModified\":\"2021-11-07T22:25:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/expanded-response-options-to-opioid-harms-case-study-from-four-canadian-cities\\\/\"},\"wordCount\":123,\"publisher\":{\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/expanded-response-options-to-opioid-harms-case-study-from-four-canadian-cities\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.drugpolicy.ca\\\/wp-content\\\/uploads\\\/2020\\\/07\\\/Screen-Shot-2020-07-02-at-9.00.04-AM.png\",\"keywords\":[\"miscellaneous\",\"safe supply OAT and iOAT\",\"safer drug use\"],\"articleSection\":[\"covid research\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/expanded-response-options-to-opioid-harms-case-study-from-four-canadian-cities\\\/\",\"url\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/expanded-response-options-to-opioid-harms-case-study-from-four-canadian-cities\\\/\",\"name\":\"Expanded Response Options to Opioid Harms: Case Study from Four Cities - Canadian Drug Policy Coalition\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/expanded-response-options-to-opioid-harms-case-study-from-four-canadian-cities\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/expanded-response-options-to-opioid-harms-case-study-from-four-canadian-cities\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.drugpolicy.ca\\\/wp-content\\\/uploads\\\/2020\\\/07\\\/Screen-Shot-2020-07-02-at-9.00.04-AM.png\",\"datePublished\":\"2020-07-02T16:28:06+00:00\",\"dateModified\":\"2021-11-07T22:25:34+00:00\",\"description\":\"COVID-19 pandemic compounds ongoing public health crisis. There's greater need to reduce pressures on healthcare system and support PWUD | CCSA case study\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/expanded-response-options-to-opioid-harms-case-study-from-four-canadian-cities\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/expanded-response-options-to-opioid-harms-case-study-from-four-canadian-cities\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/expanded-response-options-to-opioid-harms-case-study-from-four-canadian-cities\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.drugpolicy.ca\\\/wp-content\\\/uploads\\\/2020\\\/07\\\/Screen-Shot-2020-07-02-at-9.00.04-AM.png\",\"contentUrl\":\"https:\\\/\\\/www.drugpolicy.ca\\\/wp-content\\\/uploads\\\/2020\\\/07\\\/Screen-Shot-2020-07-02-at-9.00.04-AM.png\",\"width\":922,\"height\":669},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/expanded-response-options-to-opioid-harms-case-study-from-four-canadian-cities\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Expanded Response Options to Opioid Harms: Case Study from Four Cities\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/\",\"name\":\"Canadian Drug Policy Coalition\",\"description\":\"Change policy. Save lives.\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#organization\",\"name\":\"Canadian Drug Policy Coalition\",\"url\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/drugpolicy.ca\\\/wp-content\\\/uploads\\\/2019\\\/04\\\/CDPC-logo-white-on-red-150-dpi.jpg\",\"contentUrl\":\"https:\\\/\\\/drugpolicy.ca\\\/wp-content\\\/uploads\\\/2019\\\/04\\\/CDPC-logo-white-on-red-150-dpi.jpg\",\"width\":332,\"height\":333,\"caption\":\"Canadian Drug Policy Coalition\"},\"image\":{\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#\\\/schema\\\/person\\\/c32110f234bdb1f5d978710b6b406a30\",\"name\":\"Canadian Drug Policy Coalition\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9f79e2b1a0ccc3ac68e2c3b14806186aa5e053de86cb3e0ee34e1971e8c4a3f7?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9f79e2b1a0ccc3ac68e2c3b14806186aa5e053de86cb3e0ee34e1971e8c4a3f7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9f79e2b1a0ccc3ac68e2c3b14806186aa5e053de86cb3e0ee34e1971e8c4a3f7?s=96&d=mm&r=g\",\"caption\":\"Canadian Drug Policy Coalition\"},\"description\":\"Advocating for public health- and human rights-based drug policy grounded in evidence, compassion, and social justice\",\"url\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/author\\\/canadian-drug-policy-coalition\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Expanded Response Options to Opioid Harms: Case Study from Four Cities - Canadian Drug Policy Coalition","description":"COVID-19 pandemic compounds ongoing public health crisis. There's greater need to reduce pressures on healthcare system and support PWUD | CCSA case study","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.drugpolicy.ca\/fr\/expanded-response-options-to-opioid-harms-case-study-from-four-canadian-cities\/","og_locale":"fr_FR","og_type":"article","og_title":"Expanded Response Options to Opioid Harms: Case Study from Four Cities - Canadian Drug Policy Coalition","og_description":"COVID-19 pandemic compounds ongoing public health crisis. There's greater need to reduce pressures on healthcare system and support PWUD | CCSA case study","og_url":"https:\/\/www.drugpolicy.ca\/fr\/expanded-response-options-to-opioid-harms-case-study-from-four-canadian-cities\/","og_site_name":"Canadian Drug Policy Coalition","article_published_time":"2020-07-02T16:28:06+00:00","article_modified_time":"2021-11-07T22:25:34+00:00","og_image":[{"width":922,"height":669,"url":"https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2020\/07\/Screen-Shot-2020-07-02-at-9.00.04-AM.png","type":"image\/png"}],"author":"Canadian Drug Policy Coalition","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Canadian Drug Policy Coalition","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.drugpolicy.ca\/fr\/expanded-response-options-to-opioid-harms-case-study-from-four-canadian-cities\/#article","isPartOf":{"@id":"https:\/\/www.drugpolicy.ca\/fr\/expanded-response-options-to-opioid-harms-case-study-from-four-canadian-cities\/"},"author":{"name":"Canadian Drug Policy Coalition","@id":"https:\/\/www.drugpolicy.ca\/fr\/#\/schema\/person\/c32110f234bdb1f5d978710b6b406a30"},"headline":"Expanded Response Options to Opioid Harms: Case Study from Four Cities","datePublished":"2020-07-02T16:28:06+00:00","dateModified":"2021-11-07T22:25:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.drugpolicy.ca\/fr\/expanded-response-options-to-opioid-harms-case-study-from-four-canadian-cities\/"},"wordCount":123,"publisher":{"@id":"https:\/\/www.drugpolicy.ca\/fr\/#organization"},"image":{"@id":"https:\/\/www.drugpolicy.ca\/fr\/expanded-response-options-to-opioid-harms-case-study-from-four-canadian-cities\/#primaryimage"},"thumbnailUrl":"https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2020\/07\/Screen-Shot-2020-07-02-at-9.00.04-AM.png","keywords":["miscellaneous","safe supply OAT and iOAT","safer drug use"],"articleSection":["covid research"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.drugpolicy.ca\/fr\/expanded-response-options-to-opioid-harms-case-study-from-four-canadian-cities\/","url":"https:\/\/www.drugpolicy.ca\/fr\/expanded-response-options-to-opioid-harms-case-study-from-four-canadian-cities\/","name":"Expanded Response Options to Opioid Harms: Case Study from Four Cities - Canadian Drug Policy Coalition","isPartOf":{"@id":"https:\/\/www.drugpolicy.ca\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.drugpolicy.ca\/fr\/expanded-response-options-to-opioid-harms-case-study-from-four-canadian-cities\/#primaryimage"},"image":{"@id":"https:\/\/www.drugpolicy.ca\/fr\/expanded-response-options-to-opioid-harms-case-study-from-four-canadian-cities\/#primaryimage"},"thumbnailUrl":"https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2020\/07\/Screen-Shot-2020-07-02-at-9.00.04-AM.png","datePublished":"2020-07-02T16:28:06+00:00","dateModified":"2021-11-07T22:25:34+00:00","description":"COVID-19 pandemic compounds ongoing public health crisis. There's greater need to reduce pressures on healthcare system and support PWUD | CCSA case study","breadcrumb":{"@id":"https:\/\/www.drugpolicy.ca\/fr\/expanded-response-options-to-opioid-harms-case-study-from-four-canadian-cities\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.drugpolicy.ca\/fr\/expanded-response-options-to-opioid-harms-case-study-from-four-canadian-cities\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.drugpolicy.ca\/fr\/expanded-response-options-to-opioid-harms-case-study-from-four-canadian-cities\/#primaryimage","url":"https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2020\/07\/Screen-Shot-2020-07-02-at-9.00.04-AM.png","contentUrl":"https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2020\/07\/Screen-Shot-2020-07-02-at-9.00.04-AM.png","width":922,"height":669},{"@type":"BreadcrumbList","@id":"https:\/\/www.drugpolicy.ca\/fr\/expanded-response-options-to-opioid-harms-case-study-from-four-canadian-cities\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.drugpolicy.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Expanded Response Options to Opioid Harms: Case Study from Four Cities"}]},{"@type":"WebSite","@id":"https:\/\/www.drugpolicy.ca\/fr\/#website","url":"https:\/\/www.drugpolicy.ca\/fr\/","name":"Canadian Drug Policy Coalition","description":"Change policy. Save lives.","publisher":{"@id":"https:\/\/www.drugpolicy.ca\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.drugpolicy.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.drugpolicy.ca\/fr\/#organization","name":"Canadian Drug Policy Coalition","url":"https:\/\/www.drugpolicy.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.drugpolicy.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/drugpolicy.ca\/wp-content\/uploads\/2019\/04\/CDPC-logo-white-on-red-150-dpi.jpg","contentUrl":"https:\/\/drugpolicy.ca\/wp-content\/uploads\/2019\/04\/CDPC-logo-white-on-red-150-dpi.jpg","width":332,"height":333,"caption":"Canadian Drug Policy Coalition"},"image":{"@id":"https:\/\/www.drugpolicy.ca\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.drugpolicy.ca\/fr\/#\/schema\/person\/c32110f234bdb1f5d978710b6b406a30","name":"Canadian Drug Policy Coalition","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/9f79e2b1a0ccc3ac68e2c3b14806186aa5e053de86cb3e0ee34e1971e8c4a3f7?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9f79e2b1a0ccc3ac68e2c3b14806186aa5e053de86cb3e0ee34e1971e8c4a3f7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9f79e2b1a0ccc3ac68e2c3b14806186aa5e053de86cb3e0ee34e1971e8c4a3f7?s=96&d=mm&r=g","caption":"Canadian Drug Policy Coalition"},"description":"Advocating for public health- and human rights-based drug policy grounded in evidence, compassion, and social justice","url":"https:\/\/www.drugpolicy.ca\/fr\/author\/canadian-drug-policy-coalition\/"}]}},"mfb_rest_fields":["title","yoast_head","yoast_head_json"],"_links":{"self":[{"href":"https:\/\/www.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/posts\/11676","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/comments?post=11676"}],"version-history":[{"count":14,"href":"https:\/\/www.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/posts\/11676\/revisions"}],"predecessor-version":[{"id":16994,"href":"https:\/\/www.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/posts\/11676\/revisions\/16994"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/media\/11674"}],"wp:attachment":[{"href":"https:\/\/www.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/media?parent=11676"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/categories?post=11676"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/tags?post=11676"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}